Clinical trials
Phase 2 Cytokine Release Syndrome trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2013 | 1 |
| 2020 | 20 |
| 2021 | 8 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 12 |
| Completed | 12 |
| Unknown status | 6 |
| Recruiting | 5 |
| Withdrawn | 5 |
| Not yet recruiting | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| 101 Therapeutics | 2 |
| Anthea Hospital Bari | 1 |
| Ashvattha Therapeutics, Inc. | 1 |
| BioAegis Therapeutics Inc. | 1 |
| Biocon Limited | 1 |
| Boston Medical Center | 1 |
| CHRISTUS Health | 1 |
| Children's Hospital of Philadelphia | 1 |
| Corewell Health East | 1 |
| Fort Worth Clinical Sciences Working Group | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cytokine Release Syndrome | 43 |
| COVID-19 | 22 |
| Coronavirus Infections | 8 |
| Respiratory Distress Syndrome | 8 |
| Multiple Myeloma | 5 |
| Inflammation | 3 |
| Lymphoma, Non-Hodgkin | 3 |
| Severe Acute Respiratory Syndrome | 3 |
| Communicable Diseases | 2 |
| Heart Failure | 2 |
Trials
Showing 76 to 43 of 43. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.